Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02257242
Other study ID # BrUOG 326
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 10, 2017
Est. completion date November 18, 2020

Study information

Verified date May 2022
Source Brown University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates addition of Vincristine Sulfate Liposome Injection (Marqibo®) to the standard regimen of Bendamustine and Rituximab in adult patients with indolent B-cell lymphoma. This is a dose-escalation study.


Description:

Bendamustine-rituximab is a standard chemotherapy regimen for treatment of many indolent B-cell lymphomas, but most patients experience a recurrence of the lymphoma. Vincristine sulfate has been a traditional component of chemotherapy regimens in non-Hodgkin lymphoma and it is possible that adding it to the bendamustine-rituximab regimen might provide a better quality of remissions or longer duration of remissions with acceptable toxicity. This is a phase 1, single-center, open-label, single-arm trial in patients with indolent B-cell non-Hodgkin lymphoma otherwise appropriate for bendamustine-rituximab as initial or subsequent line of therapy. Patients will receive the of rituximab and bendamustine in combination with escalating doses of vincristine sulfate liposome injection (Marqibo®). The objective of this study is to assess safety of this combination by establishing the maximum tolerated dose of vincristine sulfate liposome injection (Marqibo®) in the combination.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date November 18, 2020
Est. primary completion date August 22, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed indolent B-cell non-Hodgkin lymphoma. - Radiological measurable disease. - Previous treatment for lymphoma is allowed, with the exception of use of bendamustine within 6 months or any prior use of vincristine sulfate liposome injection - Eastern Cooperative Oncology Group performance status 0 or 1; - Life expectancy of at least 6 months; - Adequate organ and marrow function; - Women of child-bearing potential and men must agree to use adequate contraception. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - History of allergic reactions attributed to any drug used in the study. - Any lymphoma-directed therapy within 4 weeks. - Any prior treatment with vincristine sulfate liposome injection. - Prior treatment with bendamustine or vincristine sulfate within 180 days of enrollment. - Patients who are receiving any other investigational agents with the exception of endocrine therapy for breast or prostate cancer. - Central nervous system involvement. - Peripheral sensory or motor neuropathy. - History of a demyelinating condition. - Positive test for the Human Anti-Chimeric Antibody (HACA). - Patients receiving any medications or substances that are strong inhibitors or inducers of Cytochrome P450, family 3, subfamily A (CYP3A) enzyme are ineligible. - Uncontrolled intercurrent illness. - Prisoners. - Pregnant or breast-feeding women. - Known Human Immunodeficiency Virus (HIV) or active Hepatitis B infection - Any prior or active cancer, which in the opinion of the investigator would preclude safe participation in this study.

Study Design


Intervention

Drug:
Rituximab
375 mg/m2 I.V. on Day 1 of each cycle
Bendamustine
90 mg/m2 I.V. on Day 1 and 2 of each cycle
Vincristine sulfate liposome injection
Dose per dose escalation protocol, I.V. on Day 2 of each cycle

Locations

Country Name City State
United States Rhode Island Hospital and The Miriam Hospital Providence Rhode Island

Sponsors (4)

Lead Sponsor Collaborator
Brown University Rhode Island Hospital, Spectrum Pharmaceuticals, Inc, The Miriam Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose Determined as the median of the marginal posterior distribution using data from all available patients Up to 6 cycles of treatment (approximately 6 months)
Secondary Number of Participants Who Completed Six Cycles of Study Treatment Up to 6 cycles of treatment (approximately 6 months)
Secondary Response Rate Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR Up to 6 cycles of treatment (approximately 6 months)
Secondary Complete Response Rate The number of patients achieving complete response during treatment on study Up to 6 cycles of treatment (approximately 6 months)
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03484702 - Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma Phase 2
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Completed NCT06190457 - Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Completed NCT02369016 - Phase III Copanlisib in Rituximab-refractory iNHL Phase 3
Recruiting NCT01676805 - Tissue Collection for Studies of Lymph Cancer
Terminated NCT00916045 - Pilot Study of Unrelated Cord Blood Transplantation Phase 2
Withdrawn NCT00538096 - A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma Phase 1
Completed NCT00534989 - Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT N/A
Terminated NCT00529503 - A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL Phase 2
Withdrawn NCT00319332 - A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen Phase 3
Completed NCT00156013 - Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) Phase 1/Phase 2
Completed NCT00141297 - A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer Phase 1
Completed NCT00322842 - Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients Phase 2
Completed NCT02509039 - A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Phase 1
Completed NCT00268203 - Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma Phase 2
Completed NCT01573000 - A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL) Phase 2
Completed NCT03289182 - An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)